Vaccines Archives

moderna biontech personalized cancer vaccine

News and Trends 24 Mar 2020

Vaccitech’s Prostate Cancer Vaccine Shows Promise in Phase II

The UK immunotherapy company Vaccitech has announced promising initial results from a phase IIa trial of a therapeutic vaccine that could offer a new way to treat advanced prostate cancer. In the open-label trial, the University of Oxford spin-off enrolled 23 patients with advanced castration-resistant prostate cancer. The patients received the company’s viral vector vaccine […]

March 24, 2020 - 2 minutesmins - By Anita Chakraverty

News and Trends 3 Feb 2020

CureVac Bids to Develop First mRNA Coronavirus Vaccine

RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global partnership to develop an mRNA vaccine against the new coronavirus strain from China. The agreement follows on from an existing collaboration launched in 2019, when the Coalition for Epidemic Preparedness Innovations, or CEPI, granted CureVac €30M to develop facilities that […]

February 3, 2020 - 2 minutesmins - By Jonathan Smith

Startup Scout 24 Jan 2020

This Company is Using Moths to Make Vaccines

Madrid-based company Algenex is using moths as natural bioreactors to improve the speed and scalability of making proteins used in vaccines and diagnostics. Mission: To harness nature for simple, scalable, and cost-efficient recombinant protein manufacture. While many proteins are manufactured using bacteria, some are made using insect cells because these cells are sometimes better […]

January 24, 2020 - 4 minutesmins - By External Contributor

News and Trends 9 Jan 2020

Emergex Vaccines Secures €10M to Advance Synthetic Vaccine Development

The UK biotech Emergex Vaccines has raised over €9.9M in a Series A funding round, which will allow it to progress the development of vaccines against diseases such as dengue, influenza, and Ebola to phase I clinical trials. Emergex specializes in the development of ‘set-point’ vaccines, which company CEO and co-founder Thomas Rademacher describes as […]

January 9, 2020 - 3 minutesmins - By External Contributor

News and Trends 20 Dec 2019

Update: First Ever Ebola Vaccine Gets US and EU Approval

Update (20/12/2019): After getting conditional approval in Europe in November, Merck has received FDA approval for its Ebola vaccine, the first to be approved in both regions. Published on 13/11/2019 The big pharma company Merck has won a conditional marketing authorization from the European Commission for the Ebola vaccine Ervebo, the first to be approved. […]

December 20, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 13 Dec 2019

Transgene’s Cancer Vaccine Abandoned after Phase II Fail

French biotech Transgene has ceased the development of a therapeutic cancer vaccine that failed to shrink tumors in patients with lung cancer in a phase II trial. In the phase II trial, Transgene tested its therapeutic cancer vaccine in combination with chemotherapy and the checkpoint inhibitor drug nivolumab, marketed as Opdivo. The treatment failed to […]

December 13, 2019 - 2 minutesmins - By Jonathan Smith

cancer vaccine virus ervaxx cell therapy

News and Trends 6 Nov 2019

UK Biotech Launched to Target ‘Dark Antigens’ with Cancer Vaccines

The London-based startup Ervaxx has launched with a €15.8M Series A round to develop cancer vaccines and cell therapies that target ‘dark antigens’ — normally silent genes in the genome that are expressed in cancer cells. Ervaxx’s Series A round was funded by the transatlantic venture capital firm SV Health Investors, as well as an […]

November 6, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 25 Sep 2019

Danish Smallpox Vaccine Gets FDA Approval to Fight Bioterrorism

A vaccine developed by the Danish company Bavarian Nordic has received FDA approval to prevent infections by monkeypox, as well as protect against the threat of a smallpox bioterror attack. This approval makes Bavarian Nordic’s vaccine the only approved vaccine in the world for preventing monkeypox, a rare viral infection that is similar to smallpox […]

September 25, 2019 - 2 minutesmins - By Jonathan Smith

Interview 4 Sep 2019

Overcoming Clinical Setbacks to Fight Insect-Borne Diseases

Sometimes things don’t go your way in the biotech industry. The CEO of Valneva, Thomas Lingelbach, shared his experience of migrating from big pharma to biotech, and how his first biotech company weathered phase III failures to develop vaccines for neglected diseases. Once confined to the less developed regions of the world, many insect-borne diseases […]

September 4, 2019 - 9 minutesmins - By Jonathan Smith

News and Trends 22 Aug 2019

Austrian Vaccine Developer Signs Deal with MSD in ‘Blockbuster Indication’

Vienna-based Themis Bioscience will develop vaccine candidates against an undisclosed disease target in partnership with big pharma Merck Sharp & Dohme. As part of the agreement, MSD will provide research funding and make an equity investment in Themis Bioscience. In addition, Themis will be eligible to receive up to €200M in milestones, in addition to […]

August 22, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

boehringer ingelheim cancer vaccine amal therapeutics

News and Trends 16 Jul 2019

Boehringer Ingelheim Acquires Cancer Vaccine Biotech in €325M Deal

The German giant Boehringer Ingelheim has acquired the Swiss company AMAL Therapeutics and its cancer vaccine technology in a deal worth up to €325M. The deal includes €225M in upfront and developmental milestone payments, as well as up to €100M in undisclosed commercial milestone payments. AMAL’s vaccine development pipeline includes five preclinical programs. The lead […]

July 16, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 10 Jul 2019

French Startup’s Universal Flu Vaccine Development Boosted by €8M Series A

The French biotech Osivax has advanced in the race to develop a universal flu vaccine, raising €8M to achieve clinical proof-of-concept. Osivax will use most of the funding to progress its lead candidate vaccine towards market approval. Targeting all strains of influenza A viruses, the vaccine is currently in a phase I trial, with results […]

July 10, 2019 - 2 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us